EVALUATION OF FIBRINOGEN LEVEL AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS VISITING THE EASTERN REGIONAL HOSPITAL

Abstract

The elevated incidence of cardiovascular diseases and deaths among individuals with type 2 diabetes mellitus cannot be solely attributed to the prevalent conventional cardiac risk factors. It is plausible that fibrinogen and platelets might contribute to this augmented risk. The objective of this research endeavor is to examine the association between fibrinogen and platelet levels in type 2 diabetes mellitus patients, along with their interconnection with glycemic management. For this study, 146 T2DM subjects were matched with 146 controls of the same age and sex. The fibrinogen levels of all participants were measured and correlated with various parameters such as fasting blood sugar, age, and sex. The results showed that patients with type 2 diabetes mellitus had higher plasma fibrinogen levels (3.55±1.24) compared to controls (2.69±0.85). Additionally, the cases group had a higher mean platelet count (399.02±362.55) compared to controls (281.09±125.98). The study also compared the fibrinogen levels and platelet counts of patients with "Good" and "Poor" glycemic control. The "Poor" glycemic control group had a higher mean fibrinogen level of 4.50 compared to the "Good" group (3.5). However, statistical analysis showed that the observed difference in fibrinogen levels between these groups may not be statistically significant at the 5% level (p-value = 0.123). A similar pattern emerged for platelet counts, with the "Poor" group having a higher mean count (419.60) than the "Good" group (310.45). According to the study, there may be a separate relationship between platelet counts and fibrinogen levels and fasting blood sugar levels. This finding adds credence to the theory that fibrinogen may be a key factor in the elevated risk of thrombotic and cardiovascular events in vii people with type 2 diabetes mellitus. The study's conclusions are important because they may help uncover possible biomarkers for the early identification and prevention of type 2 diabetes complications